1. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Issue 10086 (10th June 2017) Authors: Jørgensen, Kristin K; Olsen, Inge C; Goll, Guro L; Lorentzen, Merete; Bolstad, Nils; Haavardsholm, Espen A; Lundin, Knut E A; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore K Journal: Lancet Issue: Volume 389:Issue 10086(2017) Page Start: 2304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗